Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

Verona Pharma Announces December 2024 Investor Conference Participation

Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler. Raghuram Selvaraju - HC Wainwright Tom Shrader - BTIG Edward Thomason - VLK Joon Lee - Truist Boobalan Pachaiyappan - Roth Capital Partners Operator Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call.

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Ohtuvayre™  (ensifentrine) launch recorded Q3 net sales of $5.6 million and  October net sales exceeded Q3

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why

Blueprint Medicines

CRISPR Therapeutics

Exelixis

Amicus Therapeutics

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet

Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why

Entero Therapeutics Inc

Oculis Holding AG

Onconetix Inc

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nea.

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Cardinal Health

Catalyst Pharmaceuticals

As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Crash In August

Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call.

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Viridian Therapeutics

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump This Quarter

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.

Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why

VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.

News for Verona Pharma Stock (VRNA)